Susan Hill

Susan Hill is Chief Executive Officer of Mestag Therapeutics. Susan joined Mestag from Gyroscope Therapeutics, where she served as Chief Business Officer and helped to drive the company’s $62m Series B. Prior, she was founding Chief Executive Officer of Orbit Biomedical ($12m Series A) and Chief Business Officer of Freeline Therapeutics. Previously, Susan served in the Business & Corporate Development team at Alexion (ALXN), and during an 8-year tenure at Merck Serono (MRK) in a series of Corporate & Business Development and Portfolio Management roles. Susan began her career in strategy consulting/M&A, followed by a 3-year tenure leading biotech seed investments. She has an MA and PhD from the University of Cambridge and is a previous Fellow of the Securities Institute.